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Liposome-mediated transfer of nitric oxide synthase gene im-
proves renal function in ureteral obstruction in rats.
Background. The protective effect of nitric oxide has been
demonstrated in several renal disease models. We augmented
renal nitric oxide production by transfer of the inducible nitric
oxide synthase (iNOS) gene into rat kidney in controls and in
unilateral ureteral obstruction (UUO).
Methods. The human iNOS gene was inserted into a pcDNA
3.1-backbone plasmid with the FLAG epitope (FLAG-iNOS).
In vitro, transduction of FLAG-iNOS was confirmed by West-
ern blot and Griess reaction. In vivo, we transfected either
FLAG-iNOS or control plasmid (CMV-LacZ), using cationic
liposomes. Urinary nitric oxide metabolites and immunohisto-
chemistry confirmed iNOS transduction. Renal function was
also assessed.
Results. In vitro, increased iNOS expression was demon-
strated in human embryonic kidney (HEK293) cells, along with
increased release of nitric oxide metabolites, NO2/NO3. In vivo,
FLAG-iNOS was detected by polymerase chain reaction (PCR)
up to 35 days after the transfection. Urine collection docu-
mented increased urinary NO2/NO3. Immunohistochemistry
localized iNOS to collecting ducts, distal tubules, and glomeru-
lus of the injected kidney. Renal function measured up to 21
days after transfection in control animals was not significantly
different between the two groups. In contrast, renal function
after 24 hours of UUO was significantly improved in FLAG-
iNOS–treated animals.
Conclusion. This study demonstrates the feasibility of
liposome-mediated iNOS gene transfer into the kidney. Fur-
thermore, the improvement of renal function in UUO demon-
strates that the transfected iNOS gene is active and suggests
that decreased iNOS activity contributes to the decreased renal
function in UUO. This iNOS construct may have therapeutic
utility in the pathophysiologic sequelae of UUO and other re-
nal diseases.
1See Editorial by Chevalier, p. 1709.
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Unilateral ureteral obstruction (UUO) is a common
clinical occurrence resulting from a variety of causes, in-
cluding congenital malformations, ureteral stones, gen-
itourinary cancers, and gynecologic disorders. UUO
results in decreased renal function and progression of
renal injury such as interstitial fibrosis and tubular apop-
tosis. Thus, effective interventions to preserve renal
function and to minimize renal injury need to be devel-
oped. Historically, many pharmacologic interventions, in-
cluding angiotensin-converting enzyme (ACE) inhibitor
[1], anti-inflammatory agents [2, 3], anti-transforming
growth factor-b (TGF-b) antibody [4], and nitric oxide
donors [1, 5], have been examined in animal models of
UUO.
Nitric oxide is a multifunctional cytokine, synthe-
sized by the action of nitric oxide synthase (NOS)
from L-arginine [6]. Nitric oxide was originally termed
endothelium-derived relaxing factor because of its potent
vasodilatory effect [7]. In UUO, nitric oxide production is
known to modify renal hemodynamics in the early phase
of obstruction [8, 9]. Furthermore, the restorative effect
of nitric oxide donors on glomerular filtration rate (GFR)
and renal blood flow (RBF) within 24 hours of UUO has
been reported [5, 9–12].
The beneficial effects of nitric oxide in UUO of longer
duration have been also demonstrated. Nitric oxide aug-
mentation has been reported to function as an antifibrotic
in UUO [1, 13]. We also showed an antiapoptotic effect
of nitric oxide in mechanically stretched rat kidney ep-
ithelial cells (NRK-52E) in vitro [14]. UUO in mice with
targeted deletion of the inducible NOS (iNOS) gene is
characterized by increased fibrosis and increased renal
tubular apoptosis, suggesting that nitric oxide normally
provides a protective effect in these processes [13, 15].
Nitric oxide augmentation is, therefore, an attractive
strategy for improving both renal function and renal dam-
age (fibrosis and apoptosis) in UUO. Pharmacologic ap-
proaches to augment nitric oxide production, including
L-arginine supplementation [12], ACE inhibitor [1], and
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Table 1. Primers and oligonucleotides used in preparation of cDNA constructs
Primer/oligonucleotide
Not I-Kozak-FLAG-hiNOS(s) 5′-ATAAGAATGCGGCCGCGCCACCATGGATTACAAGGAC
GACGATGACAAGGCCTGTCCTTGGAAATTTCTGTTC
Not I-hiNOS (AS) 5′-ATAAGAATGCGGCCGCTCAGAGCGCTGACATCTCC
AGGCT
hiNOS is human inducible nitric oxide synthase.
SNAP (nitric oxide donor) [5] have all been used in the
UUO model. In this study, we sought to transfer the iNOS
gene into the kidney to augment nitric oxide production.
There are many vectors available for gene therapy, and
reports of viral and nonviral gene therapy in the kidney
have demonstrated a limited utility of this approach [16,
17]. However, the gene for carbonic anhydrase II has
been successfully transduced into carbonic anhydrase II–
deficient animals with reversal of their acidification defect
[18]; the gene for hepatocyte growth factor (HGF) has
been used to ameliorate fibrosis in UUO [19]. We used a
liposome-mediated gene transfer of the iNOS gene intro-
duced into the kidney by an intraureteral injection and
evaluated expression of the iNOS gene product and the
effect of this expression on renal function in UUO.
METHODS
Preparation of cDNA coding human iNOS gene
Human cDNA from normal colon and kidney tissues
(Clontech, Palo Alto, CA, USA) was amplified by poly-
merase chain reaction (PCR) using an Expand Long-
Template PCR Kit (Boehringer Mannheim, Mannheim,
Germany) to amplify the coding region of previously pub-
lished human iNOS (hiNOS) (Genbank accession num-
ber L09210). Primers contained a start codon (at nu-
cleotides 210-223 in the sequence of the hiNOS) and a
stop codon (at nucleotides 3668-3645). The sense primer
contained a Not I restriction enzyme site, Kozak sequence
(GCCACC), start codon, FLAG epitope sequence, and
hiNOS sequence (Not I-Kozak-FLAG-hiNOS) (Table
1). The antisense primer contained a Not I restriction
enzyme site, stop codon, and hiNOS sequence (Not I-
hiNOS). PCR was performed using an initial denatura-
tion at 94◦C for 1 minute, one cycle of denaturation at
94◦C (2 minutes), annealing at 68◦C (30 seconds), and
expansion at 68◦C for 10 minutes, 30 cycles of denatu-
ration at 92◦C (10 seconds), annealing at 68◦C (30 sec-
onds), and expansion at 68◦C (10 minutes). Samples were
stored at 4◦C, after a final cycle that prolonged the exten-
sion time at 68◦C. PCR products were electrophoresed on
0.8% agarose gels and a band at the predicted length was
found. PCR products were purified using a gel extraction
kit (Qiagen, Valencia, CA, USA). After digestion with
Not I, cDNA was subcloned into a multicloning site of
pcDNA 3.1(−) (Invitrogen, Carlsbad, CA, USA). Trans-
formation was performed with Oneshot competent cells
(Invitrogen) which were grown on LB agar with ampi-
cillin. Minipreps of plasmid DNA were made using a plas-
mid miniprep kit (Qiagen) and evaluated by restriction
digestion for the presence of the proper insert. Plasmids
were then sequenced by automated sequence analysis
with an Applied Biosystem sequencer (ABI 373A) using
dye terminator chemistry to verify that the sequence of
the PCR product was identical to the coding sequence of
hiNOS. The three clones that most closely matched the se-
quence of hiNOS (accession D26525) were subsequently
used. According to the sequencing results, we found the
sequence of amplified cDNA using colon cDNA more
closely matched hiNOS (D26525) than hiNOS (L09210).
Clone 1 had a one nucleotide deletion in the FLAG se-
quence and one point mutation at position 2599 in hiNOS
(D26525) that altered the amino acid sequence (Pro to
Leu). Other nucleotide mutations did not alter the amino
acid sequence compared to hiNOS (D26525). Since the
deletion in FLAG was flanked by two Ssp I sites, this mu-
tation was corrected by inserting the correct sequence
from clone 2 to generate clone 4. Subsequently, the point
mutation at nucleotide 2599 was corrected by digestion
of clones 3 and 4 with Sfi I and Kpn I and insertion of the
resulting SfiI-Kpn I restriction fragment containing the
wild-type sequence from clone 3 to correct the mutation
(clone 5, FLAG-iNOS). Although clone 5 had several
mutations compared to hiNOS (D26525), the predicted
amino acid sequence completely matched that of hiNOS
(D26525) (Fig. 1).
Expression of FLAG-iNOS protein and nitric oxide
production in transfected cultured cells
FLAG immunohistochemistry. iNOS protein expres-
sion and activity were determined in human embry-
onal kidney 293 cells (HEK293) transfected with FLAG-
iNOS. HEK293 were grown in minimum essential
medium (MEM) supplemented with 10% fetal bovine
serum (FBS), and 50 U/penicillin/50 lg streptomycin per
mL. 1× 106 HEK293 were plated in six-well culture dishes
and transfected with FLAG-iNOS for 24 hours. Five mi-
crograms of cDNA was added per well with 15 lL of
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. Cells treated with liposome alone
were used as controls.
Ito et al: Liposome-mediated transfer of NOS gene improves ureteral obstruction 1367
FLAG-iNOS construct (pcDNA 3.1-backbone)
FLAG epitope
CMV promoter Human iNOS gene
(Genbank D26525)
Not I Not I
CMV-LacZ construct (pcDNA 3.1-backbone)
myc epitope
CMV promoter LacZ
Not I BamH I
Fig. 1. Structure of FLAG-inducible nitric oxide synthase (iNOS) (A)
and CMV-LacZ (B) constructs. The human iNOS gene was inserted
into pcDNA3.1-backbone plasmid with a FLAG epitope sequence.
Commercially obtained control plasmid (CMV-LacZ, pcDNA3.1/myc-
His(−)/LacZ) was used for the control in vivo experiments.
Immunocytochemistry detecting the FLAG epitope
was performed to confirm protein expression in HEK293.
Cells were fixed for 5 minutes in 4% paraformaldehyde
in phosphate-buffered saline (PBS). After fixation, cells
were washed three times (5 minutes/wash) with 0.3 mol/L
glycine and then permeabilized in 0.1% Triton-X in PBS
for 7 minutes. After three washes in PBS (5 minutes/
wash), nonspecific binding sites were blocked with 5%
bovine serum albumin (BSA) and 10% normal goat
serum (NGS) in PBS for 1 hour. Cells were then incu-
bated with 10 lg/mL anti-FLAG M5 (mouse monoclonal)
(Sigma-Aldrich, St. Louis, MO, USA) and 1% NGS in
PBS for 30 minutes. After three washes with PBS (5 min-
utes/wash), cells were incubated in a 1:500 dilution of
rhodamine-conjugated goat antimouse IgG (Jackson Im-
munoResearch Laboratories, West Grove, PA, USA) for
30 minutes and then washed three times in PBS (5 min-
utes/wash). Cells were directly observed under fluores-
cent microscopy.
Western blot. Western blot was carried out with
standard techniques as previously described [14, 15].
Antibodies to both iNOS (polyclonal) (Transduction
Laboratories, Lexington, KY, USA) (1:5000) and FLAG
(anti-FLAG M5) (1: 1000) were used.
Measurement of nitrate/nitrite (NO2/NO3). NO2/NO3
was measured in the supernatant of FLAG-iNOS–
transfected cells at 24 and 48 hours after transfection,
using the Griess reaction as previously described [14, 20,
21]. Each experiment was repeated four times.
In vivo experimental protocol 1
To determine the effect of iNOS transduction on re-
nal function, male Sprague-Dawley rats (300 to 400 g)
Table 2. In vivo Transduction of inducible nitric oxide synthase
(iNOS) or LacZ
Days after transfection CMV-LacZ FLAG-iNOS
3 daysa Group 1 (N = 7) Group 5 (N = 6)
7 daysa Group 2 (N = 5) Group 6 (N = 8)
14 daysa Group 3 (N = 6) Group 7 (N = 8)
21 daysa Group 4 (N = 8) Group 8 (N = 8)
35 daysa Not examined Group 9 (N = 4)
aRenal blood flow (RBF) and glomerular filtration rate (GFR) were measured
in groups 1 to 8 at the time noted.
Urinary nitric oxide was determined at four different time points in group
4 and group 8 rats and at a single time point (32 days) in group 9 rats (renal
function was not carried out in group 9).
were kept at constant temperature and lighting con-
ditions, and fed standard rat chow. Nine groups were
studied (Table 2). The control plasmid CMV-LacZ
(pcDNA3.1/myc-His(−)/LacZ) was obtained commer-
cially (Invitrogen). CMV-LacZ was injected with lipo-
fectin (DOTMA/DOPE) (Invitrogen) into rats in groups
1 to 4 (see surgical procedure below); the iNOS plasmid
was injected with liposome into rats in groups 5 to 9. GFR
and RBF were measured at days 3, 7, 14, and 21 after
injection by inulin and paraaminohippuric acid (PAH)
clearances, respectively (see below). A 24-hour urine for
urinary NO2/NO3 measurement was collected from rats
in group 4 and group 8, placed in metabolic cages at the
following times: 1 day prior to injection, and 3, 7, 14, and
20 days after injection. A 24-hour urine in group 9 (N = 4)
was collected at 32 days after injection. Animals in group
9 were sacrificed at 35 days after injection, and kidneys
were harvested for PCR analysis (see below).
In vivo experiment protocol 2
To determine the effect of iNOS transduction on renal
function in 24 hours UUO, two groups were studied. In
group 10 (N = 7), 50 lg of CMV-LacZ with 80 lL of li-
posome was injected intraureterally as described above.
In group 11 (N = 7), 50 lg of FLAG-iNOS was used for
intraureteral injection. Seven days following the injec-
tion, left UUO was performed, as previously described
[12]. Briefly, the left upper ureter was ligated with 3-0 silk
at the ureterovesical junction. Renal function was mea-
sured after 24 hours of UUO, following which tissues were
harvested.
Intraureteral injection of plasmid-liposome complex
Thirty to sixty minutes before ureteral injection, 50 lg
of cDNA (FLAG-iNOS or CMV-LacZ) was mixed with
80 lL of lipofectin in 400 lL of PBS for each rat. Left
ureteral injection was performed using microsurgical
methods. Rats were anesthetized intraperitoneally with
ketamine (90 mg/kg) and xylazine (4 mg/kg) and posi-
tioned supine under two heating lamps. A midline ab-
dominal incision was made. Under the microscope, the
left ureter was identified and was minimally dissected
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at the upper ureter 1 to 2 cm below the ureteropelvic
junction. The lower side of left ureter was temporarily
clamped gently by 1-0 silk suture and the liposome-DNA
complex was injected slowly into the ureter using a 30 G
needle on a 1 mL syringe. An injection was considered
successful when no, or minimal, leakage of solution was
seen from the injecting hole. After injection, the needle
hole was held gently with two fingers for 10 minutes. Af-
ter 10 minutes, the fingers were released and the suture
was removed. If leakage of solution from the hole was
observed, sterile gauze was applied and wiped several
times. When the leakage became minimal, the abdomi-
nal incision was closed. Animals were warmed up with
an underpad and observed for complete recovery and
maintained at controlled conditions. Animal treatment
adhered to approved institutional guidelines.
Renal function measurement
RBF and GFR were measured as previously described
[12]. Rats were anesthetized and positioned supine un-
der two heating lamps. The anesthesia was maintained
by half-hourly injection of a half dose of the initial in-
jection. A tracheostomy was placed and the left carotid
artery was catheterized with PE-50 tubing for blood sam-
pling. The right jugular vein was cannulated with a 24 G
angiocatheter. A bolus of lactated Ringer’s solution was
slowly injected intravenously in the amount of 1% body
weight and bolus of 1% PAH, and 1.5% inulin in lac-
tated Ringer’s was injected in the amount of 0.2% body
weight. A solution of 1% PAH and 1.5% inulin in lactated
Ringer’s was infused at 10 lL/min/100 g body weight, us-
ing a calibrated Sage 365 infuser. The infusion was main-
tained for at least 60 minutes to allow for equilibration
prior to taking urine and blood collections. The ureters
were isolated and PE-10 tubing was inserted into the right
ureter and left ureter of control rats. In obstructed rats,
PE-50 tubing was inserted into the left ureter due to its di-
latation. Urine collections were started 10 minutes after
the ureters were cannulated. Twenty-minute urine col-
lections were obtained three times from both sides, and
450 lL of arterial blood was collected at the midpoint
of each collection This amount was replaced by the in-
fused solutions, so that the rat was not volume depleted.
After measurement of renal function, both kidneys were
harvested for analysis.
Urine and plasma concentrations of PAH and in-
ulin were detected using standard chemical methods,
as described previously [12]. Briefly, PAH was de-
tected colorimetrically at 550 nm using p-dimethyl-
aminocinnamaldehyde (DACA) [22]. Inulin was detected
colorimetrically at 595 nm using anthrone solution [23].
Inulin and PAH clearances were calculated using stan-
dard formulas. For each rat the values obtained for three
clearance periods were averaged. The results were nor-
malized to body weight.
Renal morphology. After renal function measure-
ment, sections of hemisected kidneys were fixed in 10%
neutral-buffered formalin and embedded in paraffin. Sec-
tions 5 lm thick were stained with hematoxylin and eosin
and Masson’s trichrome for light microscopic analysis.
Slides were examined by a board-certified renal pathol-
ogist (S.V.S.). Histologic studies were performed in a
blinded fashion. Renal morphology, such as architecture
of tubules, interstitial fibrosis, and leukocyte infiltration,
was assessed.
Confirmation of NOS transduction in vivo
NO2/NO3 amount in 24-hour urine. A 24-hour urine
sample was collected from all rats in groups 4, 8, and 9
in a reservoir containing 2-propanol, and samples were
frozen at –80◦C until assay. Urinary NO2/NO3 levels were
measured by the Griess reaction (all samples assayed in
duplicate) and results were normalized to body weight,
as previously described [12].
PCR. Rat kidneys were harvested and were kept at
–80◦C until use. DNA isolation was performed using
the QIAamp Tissue Kit (Qiagen) according to manu-
facturer’s instructions. Isolated DNA was subjected to
PCR analysis using the following primers: (sense primer
5′-ATG GAT TAC AAG GAC GAC GAT GAC AAG
GCC-3′ and antisense primer 5′-CTT CCA CCC TGG
CCA GAT GTT CCT CTA TTT-3′) (512 bp PCR frag-
ment). The primer incorporated sequences from the ad-
jacent FLAG and iNOS regions, and thus was unique to
FLAG-iNOS. Use of this primer sequence also distin-
guished the injected FLAG-iNOS from endogenous rat
iNOS. PCR amplification was performed in a reaction
volume of 25 lL containing 200 ng of extracted DNA.
Each PCR was carried out at 35 cycles under identical
conditions. The PCR products were electrophoresed on
agarose gel (2%). After staining by ethidium bromide,
DNA bands were visualized with an ultraviolet transillu-
minator (Hoefer Scientific, San Francisco, CA, USA).
Immunostaining for the FLAG epitope in frozen sec-
tions. Immunohistochemistry for the FLAG epitope was
performed using frozen sections to confirm the expres-
sion of FLAG-iNOS protein in vivo. Frozen sections were
used due to the presence of heavy background after var-
ious antigen retrieval techniques in paraffin-embedded
tissue. Immunofluorescence was carried out in a similar
manner as described above for cultured cells. In addition,
FLAG was localized using immunoperoxidase in frozen
section using the avidin-biotin-peroxidase method, as de-
scribed below.
Immunohistochemical analysis of iNOS and
b-galactosidase in paraffin-embedded tissues
Immunohistochemical analyses detecting b-
galactosidase (b-gal) and iNOS were performed.
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Fig. 2. Expression of FLAG-inducible nitric oxide synthase (iNOS)
protein in human embryonic kidney (HEK293) cells. HEK293 were
incubated with either (A) FLAG-iNOS or (B) liposome, as described
in the Methods section. Strong expression was observed 24 hours after
FLAG-iNOS transfection using liposome.
Paraffin-embedded tissue sections were made as de-
scribed above. Immunohistochemical analyses were
performed as previously described [4, 15]. In brief, the
concentrations of primary antibodies were 1:100 for
iNOS (monoclonal) (Santa Cruz Biotechnology) and
1: 100 for b-gal (polyclonal rabbit anti-b-gal antibody)
(Chemicon international Inc., Temecula, CA, USA).
Biotinylated rabbit antimouse secondary antibody
(Vector Laboratories, Burlingame, CA, USA) was used
for iNOS and biotinylated goat antirabbit secondary
antibody (Vector Laboratories) were used for b-gal
staining. Avidin-biotin peroxidase complex was used
for both staining. Sections were developed with di-
aminobenzidene (DAB) and were counterstained by
10% hematoxylin.
Statistical analysis
All results are expressed as the mean ± SE and were
analyzed for significance (P < 0.05) using unpaired t test,
paired t test, or Mann-Whitney U test where appropri-
ate for the data set using the StatView statistics package
(Abacus Concepts, Berkeley, CA, USA).
RESULTS
In vitro iNOS transduction of HEK293 cells
Expression of iNOS and nitric oxide production in
FLAG-iNOS–transfected HEK293. The human iNOS
gene was amplified from colon cDNA, and the PCR prod-
uct subcloned into a pcDNA3.1-backbone plasmid as
described in the Methods section. To determine expres-
sion and activity of the FLAG-iNOS protein, the cDNA
construct was transfected with liposome to HEK293 cells.
Figure 2A shows fluorescent staining using a mouse mon-
oclonal antibody directed against the FLAG epitope.
Strong expression was found in more than 50% of cells,
and staining was cytoplasmic. In contrast, no expression
was seen in cells transfected with liposome only (Fig. 2B).
In Western blot analyses detecting either FLAG (Fig. 3A)
or iNOS (Fig. 3B), protein expression was confirmed in
FLAG-iNOS transfected cells. To confirm the biologic
activity of the transduced iNOS, the nitric oxide metabo-
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Fig. 3. Western blot analyses for inducible nitric oxide synthase (iNOS)
in human embryonic kidney (HEK293)-transfected cells. iNOS was de-
tected in FLAG-iNOS–transfected cells by Western blot using an an-
tibody directed against (A) the FLAG epitope or (B) iNOS. In both
cases, a band at 130 kD was detected.
Table 3. NO2/NO3 concentration in the supernatant of
FLAG-inducible nitric oxide synthase (iNOS) transfected human
embryonic kidney (HEK293)
Time after Control FLAG-iNOS
transfection lmol/L transfection lmol/L
24 hours 12.5 ± 2.9 36.7 ± 1.2a
48 hours 10.7 ± 0.5 60.0 ± 4.7b
aP < 0.001 vs. control; bP < 0.001 vs. control.
lites NO2 and NO3 were measured in the supernatant
of FLAG-iNOS–transfected cells. NO2/NO3 levels were
significantly higher in the supernatant of FLAG-iNOS–
transfected cells at 24 hours and 48 hours after transfec-
tion, as compared to cells transfected with liposome alone
(Table 3).
iNOS transduction in control rats
Following in vitro confirmation of expression and ac-
tivity of transduced iNOS, the FLAG-iNOS construct was
introduced into the kidney by intraureteral injection. A
liposome containing CMV-LacZ was used as a control.
Localization of iNOS was determined, as well as its ef-
fects on renal function.
PCR analysis. To confirm duration and expression of
FLAG-iNOS plasmid in the kidney, PCR analysis using
primers specific to the FLAG-iNOS construct was car-
ried out. As shown in Figure 4A, FLAG-iNOS cDNA
was detected for 21 days in the injected kidney after
FLAG-iNOS administration, but not after Lac-Z injec-
tion. A weak band was also detected by PCR at 35 days
after injection (data not shown). A weaker PCR band
was found in the contralateral kidney (Fig. 4B). Other
tissues which showed positive PCR expression of iNOS
were lung, spleen, and bladder (Fig. 4C).
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Fig. 4. Polymerase chain reaction (PCR)
analysis for FLAG-inducible nitric oxide syn-
thase (iNOS). FLAG-iNOS cDNA was de-
tected using PCR specific for FLAG-iNOS
plasmid. (A) FLAG-iNOS cDNA could be de-
tected 21 days after the transfection in the
injected kidney. (B) FLAG-iNOS cDNA was
detected in contralateral kidney and (C) other
organs, including lung, spleen, and bladder.
Immunohistochemical analyses for FLAG epitope in
frozen section. Having determined that mRNA for
FLAG-iNOS was present, we determined the localiza-
tion of iNOS protein in the kidney. Initially, we stained
with an anti-FLAG antibody and florescent-conjugated
secondary antibody using frozen sections. Strong stain-
ing was seen in medullary collecting duct in the FLAG-
iNOS–injected kidney (Fig. 5A). The contralateral kid-
ney of FLAG-iNOS–injected rats (data not shown) and
the LacZ-transfected kidneys (Fig. 5B) did not exhibit
medullary staining. Cortical tubules of all groups demon-
strated weak fluorescent staining, which did not appear
to increase in FLAG-iNOS–injected rats. Weak stain-
ing was noted in some glomeruli of CMV-LacZ–injected
kidneys (Fig. 5C); however, staining of glomeruli in
FLAG-iNOS–injected kidneys was consistently stronger
(Fig. 5D). Some staining was also noted in the con-
tralateral kidneys of the FLAG-iNOS–transfected groups
(data not shown). Some sections were also stained with
anti-FLAG antibody and visualized using avidin-biotin
immunoperoxidase. Staining similar to that obtained us-
ing fluorescent-conjugated antibody was found (data not
shown.).
Immunohistochemical analyses using anti-iNOS an-
tibody in paraffin-embedded sections. We also exam-
ined tissue localization of iNOS using immunoperoxidase
staining with antibodies directed against iNOS. There
was baseline staining of iNOS in CMV-LacZ–transfected
kidneys, due to the presence of endogenous iNOS.
Figure 6A shows the cortex of CMV-LacZ–transfected
kidneys. Staining for iNOS in the CMV-LacZ–injected
kidneys was uniform. In contrast, in FLAG-iNOS–
injected kidneys, distal tubules exhibited intense staining
as compared to proximal tubules in the cortex (Fig. 6B).
Collecting ducts in cortex and medulla were also strongly
positive in iNOS-injected kidneys, and staining was also
found in the Loop of Henle (Fig. 6C). Staining is pre-
sented for day 3 in these figures and was still evident at
day 7.
Immunohistochemical analyses for b-gal in paraffin-
embedded sections. Since CMV-LacZ was used as a con-
trol, the localization of b-gal in rat kidney was carried
out. b-gal was found mainly in medullary collecting ducts
of injected kidney. Obvious expression was seen at day 3
and day 7. A representative animal in group 2 is shown
in Figure 7A. No staining was noted in the contralateral
kidney (Fig. 7B).
Urinary nitric oxide after intraureteral injection. Hav-
ing demonstrated iNOS expression in kidney, we were
interested in determining its biologic activity. Therefore,
the total excretion of NO2/NO3 in a 24-hour urine speci-
men was determined in consecutive samples from animals
in groups 4 and 8. In CMV-LacZ–transfected animals,
there was no increase in urinary NO2/NO3 over a 21-day
period (Fig. 8). In contrast, following FLAG-iNOS trans-
duction, urinary nitric oxide was significantly elevated at
days 7, 11, 14, and 20 when compared both to preopera-
tive sampling and to Lac-Z controls (P < 0.05). A single
measurement of urinary NO2/NO3 in group 9 rats demon-
strated a continued elevated urinary NO2/NO3 at day 32.
These results demonstrate that nitric oxide production
was augmented after FLAG-iNOS transfection.
Nitric oxide output from FLAG-iNOS and CMV-LacZ–
transfected kidneys. To evaluate nitric oxide synthesis
by FLAG-iNOS–transfected kidney, nitric oxide output
from injected kidneys was measured using urine collected
by cannulation of the ureter on the injected side. Nitric ox-
ide output from FLAG-iNOS–transfected kidney was sig-
nificantly higher (4.41 ± 2.26 pmol/g kidney weight/hour,
N = 6) than that from CMV-LacZ–transfected kidney
(0.40 ± 0.07 pmol/g kidney weight/hour, N = 6) (P <
0.01), suggesting that nitric oxide production was in-
creased in FLAG-iNOS–transfected kidneys.
Renal morphology. We examined the effect of
FLAG-iNOS expression on renal morphology in nor-
mal rats. In FLAG-iNOS–transfected groups, especially
at day 3 and day 7, dilatation of collecting ducts was
seen and distal tubules also had a slight dilatation.
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D
Fig. 5. Immunolocalization of FLAG-inducible nitric oxide synthase
(iNOS) protein in frozen sections of kidney. iNOS was visualized using
an antibody to FLAG, and was detected by immunofluorescence as
described in the Methods section. (A) Strong expression was seen in
FLAG-iNOS–transfected kidneys at day 3. The expression was mainly
in medullary collecting ducts (B) No expression was seen in medulla
of the CMV-LacZ–transfected kidney. (C) Weak staining was noted
in glomeruli of CMV-LacZ–injected kidney. (D) Stronger glomerular
staining was noted in the FLAG-iNOS–injected kidney. In addition,
cortical tubules had weak baseline fluorescence (C and D).
CMV-LacZ–transfected groups showed similar findings,
but the collecting ducts in FLAG-iNOS–transfected
groups appeared to be more dilated than CMV-LacZ
groups (data not shown). We also examined interstitial
fibrosis by Masson’s trichrome staining. Some fibrosis
in medulla was seen in injected kidneys of some ani-
mals in both FLAG-iNOS–transfected and CMV-LacZ–
transfected groups at 7, 14 and 21 days (data not shown).
Renal function after intraureteral injection in rats with-
out UUO. We examined the effect of FLAG-iNOS trans-
fection on renal function in normal rats as compared to
CMV-LacZ–injected rats. At day 3, RBF was found to be
0.82 ± 0.05 mL/min/100 g in the uninjected kidney of the
Lac-Z group, compared with 0.83 ± 0.05 mL/min/100 g in
the FLAG-iNOS group (Fig. 9A). RBF was slightly, but
not significantly, decreased in the injected kidney of the
FLAG-iNOS group. In the Lac-Z–injected group, there
was a significant decrease in RBF as compared to the
uninjected side. When RBF was compared between Lac-
Z and iNOS-injected groups, no significant differences
were noted at any time points examined (through 21 days)
(Fig. 9A). Similar findings were obtained when GFR was
measured (Fig. 9B). These results demonstrate that iNOS
transfection had no significant effect on GFR and RBF
in normal rats when compared to CMV-LacZ groups, de-
spite the histologic changes noted above.
A
B
C
Fig. 6. Immunolocalization of inducible nitric oxide synthase (iNOS)
protein in paraffin-embedded sections of kidney. iNOS was visualized
using an antibody to iNOS, and was detected by immunoperoxidase as
described in the Methods section. Representative picture from rats 3
days after injection is shown. (A) Uniform staining was noted in CMV-
LacZ–injected kidney. (B and C) In FLAG-iNOS–injected kidney, in-
creased staining was noted in distal tubules and collecting ducts in both
the cortex (B) and medulla (C). Abbreviations are: PT, proximal tubule;
DT, distal tubule; CD, collecting duct; LH, loop of Henle (in C).
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Fig. 7. Immunolocalization of b-galactosidase (b-gal) in paraffin-
embedded sections of kidney. b-gal was visualized by immunoperox-
idase as described in the Methods section. A representative picture
from rats 7 days after injection is shown. (A) In the injected kidney,
b-gal was mainly expressed in medullary collecting ducts. (B) In the
contralateral kidney, no staining was noted.
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Fig. 8. Comparison of urinary nitric oxide (NO2/3) excretion between
CMV-LacZ and FLAG-inducible nitric oxide synthase (iNOS)–injected
groups. Urinary nitric oxide metabolites were analyzed in a 24-hour
urine sample as described in the Methods section. There was signif-
icantly more urinary NO2/3 excretion in the FLAG-iNOS–injected
group as compared to the CMV-LacZ group. Increased NO2/3 excre-
tion was sustained for 32 days. ∗P < 0.05 vs. day 0; #P < 0.05 vs. same
day with CMV-LacZ treatment.
Effect of iNOS transduction on renal function in rats
with UUO
Twenty-four hours after UUO, both RBF and GFR
have been shown to decline. To determine if iNOS trans-
duction would mitigate the decreased renal function, ei-
ther FLAG-iNOS or CMV-LacZ was administered into
the ureter of two groups of rats. At 7 days, UUO was car-
ried out, and renal function measured at 24 hours after
UUO.
Immunohistochemical analyses in group 10 and group
11 for FLAG epitope in frozen section. To determine
FLAG-iNOS expression in the injected kidney after
24 hours of UUO, immunohistochemical analysis for
the FLAG epitope was performed in frozen sections.
Strong expression was seen in medullary collecting ducts
(Fig. 10A). In contrast, no staining was seen in LacZ-
CMV–transfected kidney (Fig. 10B).
LacZ - UK iNOS - UK LacZ - IK iNOS - IK
0
1
2
R
BF
,
 
m
L/
m
in
/g
Day 3
Day 7
Day 14
Day 21
A
LacZ - UK iNOS - UK LacZ - IK iNOS - IK
0.0
0.1
0.2
0.3
0.4
0.5
0.6
G
FR
, m
L/
m
in
/1
00
g
Day 3
Day 7
Day 14
Day 21
B
*
Fig. 9. Renal function in normal rats after either CMV-LacZ or FLAG-
inducible nitric oxide synthase (iNOS) injection. Renal blood flow
(RBF) and glomerular filtration rate (GFR) were measured from 3
to 21 days after injection of either CMV-LacZ or FLAG-iNOS as de-
scribed in the Methods section. (A) RBF measurements demonstrated
no significant effects of FLAG-iNOS injection. A similar finding was
noted when (B) glomerular filtration was assessed. Abbreviations are:
UK, uninjected kidney; IK, injected kidney, ∗P < 0.05 compared to
uninjected kidney.
Renal function after 24 hours UUO in posttransfected
animals. In the Lac-Z–injected rats, it can be seen that re-
nal blood flow is decreased from 0.94 ± 0.09 mL/min/100 g
in the contralateral kidney to 0.29 ± 0.04 mL/min/100 g
in the obstructed kidney (Fig. 11); this is as previously re-
ported in a 24-hour UUO model. In the FLAG-iNOS in-
jected obstructed kidney, the decline in RBF as compared
to the contralateral kidney was significantly attenuated in
comparison to the CMV-LacZ–transfected animals (P <
0.05). The decline in GFR in the obstructed kidney was
also significantly attenuated by injection of FLAG-iNOS,
when compared to CMV-LacZ–transfected animals
(0.15 ± 0.02 mL/min/100 g vs. 0.07 ± 0.01 mL/min/100 g,
P < 0.01) (Fig. 11). In contralateral kidneys, there was
no significant difference between the two groups in both
RBF and GFR, as was found in control rats. These
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Fig. 10. Immunolocalization of FLAG-inducible nitric oxide synthase
(iNOS) protein in transfected kidneys after 24 hours of UUO. FLAG-
iNOS protein was localized by immunofluorescence at 8 days after injec-
tion (coinciding with 24 hours of UUO). (A) iNOS was clearly expressed
in medulla of FLAG-iNOS injected kidney. (B) In contrast, no staining
was seen in CMV-LacZ–injected kidney.
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Fig. 11. Renal function at 24 hours after UUO following either CMV-
LacZ or FLAG-inducible nitric oxide synthase (iNOS) injection. CMV
or LacZ was injected intraureterally. At 7 days after injection, the ureter
was ligated and renal function measured at 24 hours. Both renal blood
flow (RBF) and glomerular filtration rate (GFR) were significantly de-
creased in the obstructed kidney of CMV-LacZ rats as compared to the
contralateral kidney. The decreased renal function of the obstructed
kidney was significantly attenuated in FLAG-iNOS–injected rats com-
pared to CMV-LacZ rats. Abbreviations are: CK, contralateral kidney
(LacZ; iNOS); PTK, previously transfected, obstructed kidney (LacZ;
iNOS). ∗P < 0.05 compared to contralateral kidney; ∞P < 0.05, com-
pared to LacZ-treated obstructed kidney.
results demonstrate the protective effect of iNOS on re-
nal function.
DISCUSSION
Ureteral obstruction is characterized by both changes
in renal function and by interstitial fibrosis and renal
tubular atrophy [24, 25]. Nitric oxide has been shown to
modulate the renal hemodynamic response and the cellu-
lar damage associated with UUO. Thus the present study
was designed to demonstrate that NOS, the enzyme re-
sponsible for nitric oxide synthesis, could be transduced
into the kidney, and that this transduction would have a
beneficial effect on renal function. Using a liposomal vec-
tor we demonstrated transduction of iNOS and increased
urinary nitric oxide metabolite excretion as well as an
attenuation of the decline in both RBF and glomerular
filtration which occur within 24 hours of UUO. These re-
sults show that iNOS transduction is both possible, and
effective in the short term. These results will be followed
by longer-term studies on the histopathologic effects of
UUO.
In the present study, we used a cationic liposomal vec-
tor (DOTMA/DOPE) to effect iNOS gene transfer us-
ing a retrograde delivery through the ureter. iNOS was
strongly expressed in the inner medulla, with less expres-
sion at the corticomedullary junction. Lai et al [18], using
the same vector and route of administration to deliver
the carbonic anhydrase II gene in mice, noted a similar
distribution. A similar finding was also noted [abstract;
Lipkowitz MS, el al, J Am Soc Nephrol 10:447A, 1999], us-
ing adeno-associated viral vector. Moullier et al [26] used
replication-defective adenoviral vector. Using this route
of administration, the inner medulla is the first region ex-
posed to the DNA/liposome; therefore it is not surprising
that the strongest expression is in the inner medulla. Ad-
ditional staining was noted in collecting ducts and in distal
tubules. No obvious staining was seen in interstitium and
blood vessels. In the previous reports, distribution of the
gene product appeared to be limited to the medulla. This
suggests that either species differences or differences in
the gene being transduced may be responsible for the
wider distribution noted in this study.
We attempted to determine if there was glomerular
expression of the transduced iNOS. When previous in-
vestigators targeted the glomeruli, they have introduced
the vector in almost all cases through the renal artery [16].
In the present study, there was glomerular expression of
FLAG-iNOS in the injected kidney; however, there was
also slight staining in glomeruli in CMV-LacZ–injected
kidneys. Although the intensity of glomerular staining
in FLAG-iNOS–injected animals was higher than that
in CMV-LacZ–injected animals, we could not definitely
conclude that the staining was a result of direct transduc-
tion of FLAG-iNOS into the glomerulus. It is also possi-
ble that FLAG-iNOS was transfected to other organs in
addition to the kidney; protein expressed in transfected
tissues could have been released to blood stream and
then trapped by bilateral glomeruli. This phenomenon
has been previously observed after adenoviral transfec-
tion of b-gal into the liver [27].
While examining results of the PCR experiments, con-
tralateral kidney expression of iNOS was also noted. PCR
studies also demonstrated FLAG expression in other or-
gans, including lung, spleen, and bladder. Staining in lung
and bladder were carried out, and there was no detectable
staining in these organs; spleen was not examined. Thus, it
appears, that there was no or minimal protein expression
in tissues, despite the positive results in the PCR analysis.
In the clinical situation, retrograde pyelography some-
times results in reflux to the venous system surrounding
1374 Ito et al: Liposome-mediated transfer of NOS gene improves ureteral obstruction
the collecting system, when a large amount of contrast
media is retrogradely infused. Therefore, it is possible
that the reflux to the venous system by retrograde injec-
tion might result in systemic delivery of DNA/liposome
complex.
There are reports of protection of kidneys in UUO by
delivery of genes for secreted proteins to skeletal muscle.
Ga et al [19] recently reported that HGF gene transfer
with hemagglutinating virus of Japan (HVJ)-liposome via
intramuscular injection successfully improved renal in-
jury in UUO. Only the obstructed kidney was examined
in that study, so it is not clear if any organs other than the
obstructed kidney were affected by intramuscular gene
delivery. Secretory proteins such as HGF can be delivered
by intramuscular gene therapy and can affect the kidney
through the systemic blood flow. However, in case of in-
tracellular protein such as iNOS or membrane proteins,
the protein expressed in muscle cells would not be likely
to affect the kidney. Moreover, the systemic increase in
a secreted protein can affect other organs in addition to
targeted organ and may develop some unexpected side
effects.
In addition to studying tissue localization of iNOS, we
examined the duration of iNOS expression. This was done
both by PCR, examining persistence of FLAG-iNOS and
by determining urinary excretion of nitric oxide metabo-
lites. In the present study, following a single injection
of cDNA/liposome complex, we demonstrated FLAG-
iNOS plasmid by PCR even at 5 weeks after injection.
Urinary nitric oxide was elevated at least 32 days after
transfection. In viral-mediated gene delivery systems us-
ing adenovirus or retrovirus vector, no long-term expres-
sion has been shown in kidney-targeted gene therapy. As
has been shown with adenoviral gene delivery to other
tissues, duration of gene expression was limited to sev-
eral weeks, most likely due to a lack of integration into
the host genome and an immune response to adenovi-
ral proteins. In liposome-mediated gene delivery to the
kidney, Lai, Moeckel, and Lien [28] have demonstrated a
1-month expression of b-gal gene in mice and our results
were similar.
We also demonstrated increased release of nitric oxide
metabolites directly from the injected kidney by examin-
ing urinary nitric oxide obtained from individual ureters.
Urinary nitric oxide metabolites were significantly higher
in injected kidneys after FLAG-iNOS as compared to
LacZ-injected kidneys. This suggests that the increased
urinary nitric oxide results, at least in part, from increased
renal nitric oxide synthesis, thus confirming an increase
in functional NOS in the injected kidney.
Despite increased NOS as demonstrated above, gene
transfer of iNOS did not alter the baseline renal function
in control rats as compared with CMV-LacZ–injected
rats. There was a slight reduction in both RBF and GFR
at 3 days after intraureteral injection in both FLAG-
iNOS and CMV-LacZ groups, which was significant only
in the Lac-Z group. An apparent inflammatory change
around the injected ureter, especially at the injection site,
was seen. Therefore, a temporary decrease of urine flow
might have occurred due to a disturbance of urine flow
by inflammatory changes such as tissue edema. Despite
the histologic changes noted, RBF and GFR remained
stable over the 21 days of the experiment suggesting
that there were no sustained harmful effects on the kid-
ney. These results confirm previous findings that increas-
ing the availability of nitric oxide in the normal kidney
does not increase RBF and suggest that the baseline sup-
ply of nitric oxide is sufficient to maintain normal renal
function.
We also examined the effect of iNOS transduction on
renal function in the setting of 24 hours of UUO, a time
in which both RBF and GFR are considerably reduced.
We have shown in earlier studies that feeding arginine for
2 weeks prior to UUO can ameliorate the reduced renal
function found at 24 hours of UUO [12]. In selecting the
optimal time for injecting the liposome, we chose to use a
7-day time point. We thought that this would optimize the
expression of NOS, but would allow the kidney some re-
covery from the inflammation seen, especially at day 3. In
contrast to the effect of FLAG-iNOS expression on renal
function in the normal kidney, its expression significantly
improved RBF and GFR in the setting of UUO. Interest-
ingly, we have previously demonstrated that at 18 hours
of UUO in a dog model, providing exogenous arginine
increases RBF in the obstructed kidney [8]. The present
study demonstrates that providing more iNOS is another
way to increase renal blood flow in UUO. As we have
demonstrated, with increased glomerular NOS following
iNOS transduction, there could be a direct effect of nitric
oxide to increase RBF and GFR. All three of these stud-
ies emphasize the importance of increasing nitric oxide
to reverse the decrease in renal function in UUO. Nitric
oxide augmentation by the nitric oxide donor, L-arginine,
reportedly improved tubular apoptosis and indicators of
interstitial fibrosis in UUO model [1]. Both antiapoptotic
and antifibrotic effects of nitric oxide in the setting of
UUO were demonstrated by our previous experiments
using iNOS knockout mice [13].
Nonviral gene transfer may come to be a useful ther-
apy in the kidney, owing to the safety of liposome-
mediated therapy, and the ability to repeat injections. We
have demonstrated increased urinary nitric oxide for at
least 1 month in rats following intraureteral transduction
of FLAG-iNOS, and significant improvement of renal
function in a 24-hour UUO model. To mimic the clinical
situation more directly, we would need to induce UUO
experimentally and then provide gene therapy. Such stud-
ies are planned. However, if renal obstruction occurs
which can not be relieved immediately, providing a source
of nitric oxide could be beneficial, prior to and following
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relief of obstruction. Induction of NOS for 1 month may
be sufficient in this situation. However, in chronic or con-
genital disorders, which would require long-term gene
expression, repeated liposome administration is possible
or the NOS gene could be delivered by other vectors such
as retrovirus or adeno-associated virus.
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